-

06:28:36 PM

LIVE Real Time PKI Stock Market News

PKI - Perkinelmer, Inc.

05/04/21 5:00 PM

NYSE : PKI

PerkinElmer to Host Virtual Investor and Analyst Day

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will host a virtual Investor and Analyst Day on Thursday, June 24, 2021 from 8:30 a.m. to 12:00 p.m. ET.The virtual format will feature presentations by members of

RHEA-AI

neutral

05/04/21 4:05 PM

NYSE : PKI

PerkinElmer Announces Financial Results for the First Quarter of 2021

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the first quarter ended April 4, 2021.The Company reported GAAP earnings per share from continuing operations of $3.37, as compared to GAAP earnings per share from

RHEA-AI

neutral

04/29/21 4:15 PM

NYSE : PKI

PerkinElmer Board Declares Quarterly Dividend

The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock April 29, 2021. This dividend is payable on August 6, 2021 to all shareholders of record at the close of business on July 16, 2021.About PerkinElmerPerkinElmer, Inc.

RHEA-AI

neutral

04/29/21 9:15 AM

NYSE : PKI

Oxford Immunotec's T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell Response and COVID Vaccination in Ethnic Minority Groups

Oxford Immunotec a global, high-growth diagnostics company part of PerkinElmer (NYSE: PKI), today announced that its T-SPOT (R) Discovery SARS-CoV-2 kit will be used for T cell testing in the DIRECT study. Oxford

RHEA-AI

neutral

04/27/21 9:15 AM

NYSE : PKI

Oxford Immunotec's T-SPOT Discovery SARS-CoV-2 Test is Used in UK Com-COV Clinical Trial to Investigate the T Cell Response in Different Combinations of Approved COVID-19 Vaccines for the First and Second Doses

Oxford Immunotec, a global, high-growth diagnostics company part of PerkinElmer (NYSE: PKI), today announced that its T-SPOT (R) Discovery SARS-CoV-2 kit will be used for T cell testing in the UK Com-COV trial. The

RHEA-AI

neutral

04/21/21 8:00 AM

NYSE : PKI

PerkinElmer to Present at BofA Securities 2021 Virtual Health Care Conference

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the BofA Securities 2021 Virtual Health Care Conference on Wednesday, May 12, 2021 at 9:30 a.m. ET.Prahlad Singh, president and chief executive officer of

RHEA-AI

neutral

04/13/21 4:15 PM

NYSE : PKI

PerkinElmer Provides First Quarter Update and Schedules Earnings Call for Tuesday, May 4, 2021

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of 98% and 90%, respectively, for the first quarter ended April 4, 2021.PerkinElmer's strong revenue performance was driven by

RHEA-AI

neutral

03/29/21 11:33 AM

NYSE : PKI

Horizon Discovery Extends Gene Modulation Portfolio with Industry First Synthetic Single Guide RNA and Patent Pending dCas9 Repressor for CRISPR Interference

Horizon Discovery, a PerkinElmer, Inc. (NYSE:PKI) company, today announced that its gene editing and modulation portfolio is expanding to include a new family of CRISPR modulation (CRISPRmod) reagents for CRISPR interference (CRISPRi). CRISPRi enables scientists to better understand the biological

RHEA-AI

neutral

03/09/21 8:00 AM

NYSE : PKI

PerkinElmer Launches Comprehensive Solutions for Detecting SARS-CoV-2 Mutations

PerkinElmer, Inc. (NYSE:PKI) today announced the launch of two Research Use Only (RUO) solutions, PKamp(TM) VariantDetect(TM) SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX (R) Variant-Seq(TM) SARS-CoV-2 Kit. Using nucleic acid extracted from samples that previously tested positive,

RHEA-AI

neutral

03/09/21 8:00 AM

NYSE : PKI

PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC

PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). PerkinElmer originally announced its intent to acquire Oxford

RHEA-AI

neutral